Preclinical data using the CD11b agonist ADH‐503 in animal models have demonstrated benefits in the lung[16] and pancreatic cancers.[11a] The identification of efficient immunotherapeutics will be tremendously improved by using pre‐clinical models that replicate components of the human tumor‐immune landscape. Here, ITGAM is linked to pancreatic neoplasm.